Description
Mexicor Pharmacodynamics
Antioxidant drug. Mexikor® reduces manifestations of oxidative stress by inhibiting free-radical lipid peroxidation and increasing the activity of antioxidant enzyme system. Mexicor® improves cellular energy exchange by activating the energy-synthesizing functions of mitochondria, increasing compensatory activation of aerobic glycolysis and reducing the degree of inhibition of oxidative processes in the Krebs cycle.
The energy-synthesizing effect of the drug is associated with increased delivery and consumption of succinate by cells, realization of the phenomenon of rapid oxidation of succinate acid by succinate dehydrogenase, as well as with activation of the mitochondrial respiratory chain. When Mexicor® dissociates in the cell into succinate and 3-oxypyridine derivative (base), the base exhibits a powerful antioxidant effect that stabilizes cell membranes and restores functional activity of cells. It reduces cell membrane viscosity, increases its fluidity and modulates membrane-bound enzymes (calcium-independent phosphodiesterase, adenylate cyclase, acetylcholinesterase), ion channels and receptor complexes, which helps to maintain structural and functional integrity of biomembranes, improves neurotransport and synaptic transmission.
The drug improves cerebral metabolism and blood supply to the brain, improves microcirculation and rheological properties of blood, reduces platelet aggregation.
It improves functional state of ischemic myocardium, cardiac contractile function and reduces manifestations of systolic and diastolic left ventricular dysfunction. In conditions of coronary insufficiency it increases collateral blood supply to the ischemic myocardium and activates energy-synthesizing processes in the ischemic zone, which helps to preserve the integrity of cardiomyocytes and maintain their functional activity. It effectively restores myocardial contractility in reversible cardiac dysfunction, which represents a significant reserve for increasing the contractility of the heart in patients with CHD complicated by heart failure.
In patients with stable angina pectoris increases exercise tolerance and antianginal activity of nitrates, improves blood rheological properties. Adding Mexicor® to standard therapy of CHD improves clinical condition of patients, increases exercise tolerance and improves quality of life.
Mexicor® stabilizes membrane structures of the vascular wall, inhibits platelet aggregation, normalizes microcirculatory disorders in the early stages of atherogenesis, has hypolipidemic effect, reduces total cholesterol and LDL.
Mexicor® has neuroprotective effect on the functional activity and metabolism of the ischemic brain, increases resistance of cerebral blood flow in hypoperfusion, prevents reduction of cerebral blood flow in reperfusion period after ischemia. The drug promotes adaptation to the damaging effects of ischemia by slowing the depletion of carbohydrate stores, blocking the post-ischemic fall in glucose and oxygen utilization by the brain and preventing the progressive accumulation of lactate. At the same time, indicators of autoregulatory responses of cerebral vessels are improved.
Mexicor® possesses nootropic properties, prevents and reduces disturbances of learning and memory processes in acute and chronic cerebral vascular diseases, in mild and moderate cognitive disorders of various genesis, has antioxidant effect, increases attention concentration and performance.
Inclusion of Mexicor® preparation in complex therapy of patients with acute stroke reduces intensity of clinical manifestations of stroke and improves rehabilitation period.
Mexicor® has a selective, not accompanied by sedation and myorelaxation, anxiolytic effect, eliminates anxiety, fear, tension, restlessness, improves adaptation and emotional status.
Indications
– CHD (in the complex therapy);
– Ischemic stroke (in the complex therapy);
– discirculatory encephalopathy;
– Mild to moderate cognitive impairment
Contraindications
– Acute liver dysfunction;
– Acute renal dysfunction;
– Children and adolescents under 18 years of age (efficacy and safety not established);
– pregnancy;
– Lactation period (breast-feeding);
– Hypersensitivity to the components of the drug.
Dosage and administration method
- Mexicor® is administered orally. The initial dose is 100 mg (1 capsule) 3 times per day.
- Then the dose should be gradually increased according to the clinical course of the disease and tolerability of therapy. The maximum daily dose should not exceed 800 mg, a single dose – 200 mg. The daily dose of the drug should preferably be divided into several doses during the day. The course of treatment with Mexicorom end gradually, reducing daily dose of the drug by 100 mg.
- The duration of Mexicor treatment course should be at least 1.5-2 months if it is used as part of complex therapy of CHD and cerebral circulation disorders. Repeated courses (as recommended by the doctor) should preferably be carried out in spring and autumn periods.
- In complex therapy of discirculatory encephalopathy, mild and moderate cognitive disorders, Mexicor® is prescribed without limitation in duration of treatment, in dose of 100 mg 3-4 times per day.
